|
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems Clinical research trials and A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems. A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems clinical trial. Participants typically obtain the most effective healthcare available for their A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems  A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems
For Condition: HIV Infections,Chickenpox
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.
Details: Patients are randomized to receive either 882C87 or acyclovir with corresponding placebos for 14 days, with two hundred patients in each of the two groups. They are stratified by presence or absence of HIV infection. Patients undergo 6 months of follow-up.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Acute localized herpes zoster or rash present less than 72 hours, verified by clinical diagnosis. - Immunocompromised condition primarily as a result of documented HIV infection, malignancy, chemotherapy or radiation therapy, solid organ or bone marrow transplant, or chronic immunosuppressive therapy. - Life expectancy of at least 6 months. - Ability to cooperate with the requirements of the study. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Evidence of cutaneous or visceral dissemination (more than 20 discrete lesions outside adjacent dermatomes). - Acute, life-threatening condition. - Significant malabsorption syndrome or other gastrointestinal dysfunction that may severely reduce drug absorption. - Intolerance of oral medication. Concurrent Medication: Excluded: - Tricyclic antidepressants or anti-epileptics. - Topical applications to the zoster lesions that would obscure evaluation. - Fluorouracil and flucytosine. - Systemic therapy with agents with antiherpetic activity (from 2 weeks prior to first dose to day 28 of study). - Probenecid or other drugs likely to affect elimination of study drugs (from 2 days prior to first dose to day 14 of the study). - Capsaicin (Zostrix). - Warfarin (Coumadin) during 14 days of treatment. Patients with the following prior conditions are excluded: History of intolerance, hypersensitivity, or severe drug reaction to acyclovir. Prior Medication: Excluded: - Systemic therapy with agents with antiherpetic activity (including interferon) within the past 2 weeks. - Probenecid or other drugs likely to affect the elimination of 882C87 or acyclovir within the past 48 hours. - Drugs likely to interact with 882C87 (e.g., fluorouracil or flucytosine) within the past 7 days. - Zoster immune globulin or zoster immune plasma within the previous month. History of alcohol or drug abuse within the previous 6 months or current methadone therapy.
Total Enrollment: 400
Location and Contact Information:
Simon - Williamson Clinic
Birmingham, Alabama, 35211
United States
Rhinelander Med Ctr
Rhinelander, Wisconsin, 54501
United States
New Mexico Med Group
Albuquerque, New Mexico, 87110
United States
Med Associates Clinic
Dubuque, Iowa, 52001
United States
Jordon Diagnostics and Research Inc
High Point, North Carolina, 27262
United States
Oregon Research Group
Eugene, Oregon, 97401
United States
Roger Williams Med Ctr
Providence, Rhode Island, 02908
United States
SORRA / NC Research Ctr
Birmingham, Alabama, 35234
United States
Med Consultants LTD
Milwaukee, Wisconsin, 53215
United States
Univ TX Med Branch
Nassau Bay, Texas, 77058
United States
Hanover Med Specialists
Wilmington, North Carolina, 28401
United States
Washington Univ
St. Louis, Missouri, 63110
United States
Infections Ltd / Physicians Med Ctr
Tacoma, Washington, 98405
United States
Cedars Sinai Med Ctr
Los Angeles, California, 90048
United States
Clinical Research Consultants
Trumbull, Connecticut, 06611
United States
Oregon Health Sciences Univ
Portland, Oregon, 97201
United States
Vanderbilt Med Ctr
Nashville, Tennessee, 37232
United States
Saint Francis Mem Hosp
San Francisco, California, 94109
United States
MacGregor Med Association
Houston, Texas, 77054
United States
Sunnyvale Med Clinic
Sunnyvale, California, 94086
United States
Silver Lake Med Inc
Providence, Rhode Island, 02909
United States
Univ of Arizona / Univ Med Ctr
Tucson, Arizona, 85724
United States
N Texas Ctr for AIDS & Clin Rsch
Dallas, Texas, 75219
United States
Oschner Clinic
New Orleans, Louisiana, 70121
United States
AIDS Community Research Consortium
Redwood City, California, 94063
United States
Additional Information:
Study ID Numbers: 130A;
Study Start Date:
Record last reviewed: May 1994
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002315
Other Chickenpox Studies:
1. Reducing the Transmission of HIV in China
2. Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection
3. Longitudinal Study of Ocular Complications of AIDS (LSOCA)
4. A Phase I Study of the Safety of Proleukin (aldesleukin) in Combination with Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
5. Safety and Tolerance of Indinavir plus Ritonavir in HIV-Positive Patients Failing Therapy with Amprenavir, Nelfinavir, or Saquinavir
Related Studies:
Other Chickenpox Clinical Trials
Other Louisiana Clinical Trials
Other New Orleans Clinical Trials
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems
|
|
|
|
|
|
|
|
